FDA takes up peptide therapies as hype outpaces science

The FDA is establishing regulatory frameworks for peptide therapies as venture funding and clinical claims in the sector accelerate faster than evidence accumulates. This creates both a market validation signal and a compliance bottleneck for peptide-focused biotech founders.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.